Trial Profile
Radotinib Efficacy and Safety Validation in Chronic Phase Chronic Myeloid Leukemia Patients Who Are Intolerant or Resistant to at Least Two Tyrosine Kinase Inhibitors As a Third or Subsequent Line Therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Mar 2019
Price :
$35
*
At a glance
- Drugs Radotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms REVITAL
- 27 Apr 2015 New trial record